Endorex (DOR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Endorex (DOR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JMarcus who wrote ()	5/15/1999 10:44:00 PM
From: JMarcus	of 3

biz.yahoo.com During the recent shareholders meeting, Endorex management presented the results of a study published in the April 15, 1999, edition of Cancer Research, the official journal of the American Association for Cancer Research, by a group of investigators at the McArdle Laboratory for Cancer Research at the University of Wisconsin, and the Lombardi Cancer Center at Georgetown University. This study is entitled: ''Activation of the Transforming Growth Factor Signaling Pathway and Induction of Cytostasis and Apoptosis in Mammary Carcinomas Treated with the Anticancer Agent Perillyl Alcohol.'' The study reviews some of the novel mechanisms of action of POH on breast and other types of cancer. Here's a link to the Cancer Research abstract: aacr.org

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next